Deal facts
- Buyer
- Laboratory Corporation of America
- Target
- Myriad Genetics, Inc.
- Deal value
- Not disclosed
- Announced
- 20 October 2026
- Status
- Firm intention
- Sector
- Healthcare
- Country
- United States
- Consideration
- Not stated
Sources
Laboratory Corporation of America has agreed to acquire Myriad Genetics, Inc. in a transaction structured as an asset sale. Both entities are based in the United States and operate within the healthcare sector. The deal was announced on 20 October 2026. The specific financial terms, including the total deal value and the form of consideration, have not been disclosed. Consequently, no figures regarding the purchase price or currency are available for this transaction. The acquisition represents a significant move within the US healthcare landscape, involving the transfer of specific assets from Myriad Genetics to Laboratory Corporation of America. No completion date has been reported for this agreement. The transaction is currently at the firm intention stage.
Deal timeline
1 update- Firm intention
Laboratory Corporation of America firm intention to acquire Myriad Genetics, Inc.
Item 7.01 is a press release announcing the Company’s entry into the Purchase Agreement. The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by refer
Source
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
BioNTech US Inc. to acquire a Rare Pediatric Disease Priority Review Voucher from Scholar Rock Inc.
BioNTech US Inc. has agreed to buy a Rare Pediatric Disease Priority Review Voucher from Scholar Rock Inc. for $205 million in cash. Scholar Rock Inc. is a wholly owned…
- Buyer
- BioNTech US Inc.
- Target
- Rare Pediatric Disease Priority Review Voucher of Scholar Rock Inc.
- Deal value
- USD 205,000,000
- Deal type
- asset sale
Abeona Therapeutics Inc. acquires APT-1011 (ABO-801) assets of Ellodi Pharmaceuticals, L.P.
Abeona Therapeutics Inc. bought substantially all assets related to the research, development, manufacture and commercialization of APT-1011 from Ellodi Pharmaceuticals,…
- Buyer
- Abeona Therapeutics Inc.
- Target
- APT-1011 (ABO-801) assets of Ellodi Pharmaceuticals, L.P.
- Deal value
- USD 20,000,000
- Deal type
- asset sale
CorMedix Inc. to acquire substantially all assets of Heron Therapeutics, Inc.
CorMedix Inc. (Nasdaq: CRMD) and Heron Therapeutics, Inc. (Nasdaq: HRTX) announced on 9 November 2026 that they had entered into a definitive asset purchase agreement, s…
- Buyer
- CorMedix Inc.
- Target
- Substantially all assets of Heron Therapeutics, Inc.
- Deal value
- USD 222,600,000
- Deal type
- asset sale
Rockwell Medical, Inc. to acquire Vantive's in-center hemodialysis business
Rockwell Medical, Inc. signed an Equity and Asset Purchase Agreement on November 2, 2026 with Vantive Limited, a Jersey company, to acquire Vantive's in-center hemodialy…
- Buyer
- Rockwell Medical, Inc.
- Target
- Vantive in-center hemodialysis business
- Deal value
- USD 125,000,000
- Deal type
- asset sale
Biossil Labs Inc. to acquire Theriva Biologics' ribaxamase and SYN-006 assets
Theriva Biologics, Inc. (NYSE American: TOVX) sold its ribaxamase program to Biossil Labs Inc., a corporation organized under the laws of Canada, under an Asset Purchase…
- Buyer
- Biossil Labs Inc.
- Target
- Theriva Biologics ribaxamase and SYN-006 assets
- Deal value
- USD 350,000
- Deal type
- asset sale
Buyer history
Laboratory Corporation of America
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive